Search Results for "President CEO Epicentre Biotechnologies"

04:07 EDT 2nd July 2015 | BioPortfolio

Matching Channels

Drug Development for Rare Diseases

The economics of any industry relies on a large demand for a particular product; this applies to the pharmaceutical industry where efforts are focused on big and relatively straight-forward diseases...

Matching News

Liberia closes Ebola centre at epicentre of outbreak

Liberia's president on Monday announced the closure of an Ebola treatment facility which lay at the epicentre of the virus's worst outbreak in history, as the disease's spread has slowed in the countr...

ExpreS2ion Biotechnologies – production in Drosophila S2 cells

ExpreS2ion Biotechnologies is a world leading contract research organization (CRO) for the production in Drosophila Schneider-2 (S2) cells using its proprietary and complete S2 recombinant protein tec...

Adaptive Biotechnologies to purchase immunosequencing firm

Adaptive Biotechnologies said it secured $94 million in private equity funding and used the money to acquire Sequenta, an imm -More- 

Aelan enters Dx partnership with Nuclea Biotechnologies

A partnership deal was reached between Aelan Cell Technologies and Nuclea Biotechnologies to create, commercialize and suppor -More- 

Minerva Biotechnologies Corp.

Minerva Biotechnologies Corp. is engaged in the development of novel biosensors.

Adaptive Biotechnologies Series F financing

Adaptive Biotechnologies announced the completion of Adaptive’s Series F financing round with a $195 million investment to support several strategic growth initiatives. This round was led by Matrix ...

Matinas BioPharma acquires Aquarius BioTechnologies

Matinas BioPharma Holdings has acquired all of the outstanding stock of Aquarius BioTechnologies, an innovative bio-delivery drug discovery company with a novel and proprietary lipid-crystal nano-part...

Adaptive Biotechnologies acquires fellow immunosequencing firm Sequenta

Using proceeds from its concurrent $94mm Series E round, Adaptive Biotechnologies Corp. acquired fellow private clinical diagnostics developer Sequenta Inc. (immunosequencing).

Matching PubMed Articles

Nancy L. Ascher, MD, PhD: Professor and Chair, Department of Surgery, UCSF; Past-President, ASTS; President-elect, The Transplantation Society.

A New Initiative on Precision Medicine.

"Tonight, I'm launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes - and to give all of us access to the personalized information we need to kee...

Introducing the New American Nurses Association President: Pamela F. Cipriano, PhD, RN, NEA-BC, FAAN.

This month in the Magnet® Perspectives column, Pamela F. Cipriano, PhD, RN, NEA-BC, FAAAN, new President of the American Nurses Association, discusses her priorities for the future and partnerships t...

Camelid Genetics and Reproductive Biotechnologies.

Minutes of the General Assembly in Amsterdam, Wednesday, June 25th 2014, 15.30-16.15.

1) Welcome from the Congress President 2) The Minutes of the General Assembly of Toulouse, published in the Rhinology Journal of June 2013 are accepted. 3) Report of President 4) Report of General Sec...

Search Whole site using Google


Advertisement Advertisement